{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:27:54Z","timestamp":1788460074842,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.euf.2024.02.005","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T21:14:23Z","timestamp":1708722863000},"page":"325-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder\u2013wet Patients over the Age of 75 Years with Mild Cognitive Impairment"],"prefix":"10.1016","volume":"10","author":[{"given":"Saima","family":"Rajabali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prosper","family":"Asaana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Nazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5372-530X","authenticated-orcid":false,"given":"Adrian","family":"Wagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2024.02.005_b0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/nau.23897","article-title":"The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction","volume":"38","author":"D\u2019Ancona","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.02.005_b0010","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.02.005_b0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2012.04.004","article-title":"Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS","volume":"80","author":"Milsom","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.euf.2024.02.005_b0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5468\/ogs.2020.63.2.181","article-title":"A multicenter cross-sectional study on the prevalence of overactive bladder and its impacts on the quality of life in gynecologic outpatients","volume":"63","author":"Kim","year":"2020","journal-title":"Obstet Gynecol Sci"},{"key":"10.1016\/j.euf.2024.02.005_b0025","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s12325-018-0796-8","article-title":"The association between overactive bladder and falls and fractures: a systematic review","volume":"35","author":"Szabo","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.euf.2024.02.005_b0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.urology.2017.03.058","article-title":"Overactive bladder is strongly associated with frailty in older individuals","volume":"106","author":"Suskind","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.euf.2024.02.005_b0035","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1080\/03007995.2016.1226167","article-title":"Real-world characteristics of elderly patients with overactive bladder in the United States","volume":"32","author":"Ganz","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.euf.2024.02.005_b0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","article-title":"Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms","volume":"84","author":"Gravas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.02.005_b0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2022.01.045","article-title":"European Association of Urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence","volume":"82","author":"Nambiar","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.02.005_b0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1998.tb01006.x","article-title":"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride","volume":"46","author":"Katz","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.euf.2024.02.005_b0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.trci.2017.01.003","article-title":"Bladder antimuscarinics and cognitive decline in elderly patients","volume":"3","author":"Moga","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.euf.2024.02.005_b0060","article-title":"Anticholinergic drugs and risk of dementia: case-control study","volume":"361","author":"Richardson","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2024.02.005_b0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bju.15040","article-title":"Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study","volume":"126","author":"Welk","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.02.005_b0070","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41585-021-00504-x","article-title":"The cognitive effect of anticholinergics for patients with overactive bladder","volume":"18","author":"Welk","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2024.02.005_b0075","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/gerona\/glp037","article-title":"Localization of brain white matter hyperintensities and urinary incontinence in community-dwelling older adults","volume":"64","author":"Kuchel","year":"2009","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.euf.2024.02.005_b0080","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/jnnp.67.5.658","article-title":"Urinary function in elderly people with and without leukoaraiosis: relation to cognitive and gait function","volume":"67","author":"Sakakibara","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.euf.2024.02.005_b0085","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1532-5415.2008.01681.x","article-title":"Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes","volume":"56","author":"Sink","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.euf.2024.02.005_b0090","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/nau.23719","article-title":"Association between overactive bladder treatment and falls among older adults","volume":"37","author":"Jayadevappa","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.02.005_b0095","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF03261924","article-title":"Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study","volume":"32","author":"Kay","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.euf.2024.02.005_b0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","article-title":"Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects","volume":"50","author":"Kay","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.02.005_b0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2012.05.2543","article-title":"Evaluation of cognitive function in healthy older subjects treated with fesoterodine","volume":"124","author":"Kay","year":"2012","journal-title":"Postgrad Med"},{"key":"10.1016\/j.euf.2024.02.005_b0110","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/01.ju.0000148963.21096.5d","article-title":"Assessment of cognitive function of the elderly population: effects of darifenacin","volume":"173","author":"Lipton","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.02.005_b0115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/14740330903260790","article-title":"Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg","volume":"8","author":"Wesnes","year":"2009","journal-title":"Expert Opin Drug Safety"},{"key":"10.1016\/j.euf.2024.02.005_b0120","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2013.01.002","article-title":"Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and cognitive impairment in elderly people with mild cognitive impairment: the SENIOR study","volume":"64","author":"Wagg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.02.005_b0125","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","article-title":"Mild cognitive impairment\u2014beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment","volume":"256","author":"Winblad","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.euf.2024.02.005_b0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.02.005_b0135","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/archpsyc.1983.01790060110016","article-title":"The Mini-Mental State Examination","volume":"40","author":"Folstein","year":"1983","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.euf.2024.02.005_b0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression screening scale: a preliminary report","volume":"17","author":"Yesavage","year":"1982","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.euf.2024.02.005_b0145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1046\/j.1365-2125.2000.00131.x","article-title":"Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers","volume":"49","author":"Wesnes","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.euf.2024.02.005_b0150","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.euf.2024.02.005_b0155","doi-asserted-by":"crossref","first-page":"570","DOI":"10.5414\/CPP47570","article-title":"Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine","volume":"47","author":"Malhotra","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.euf.2024.02.005_b0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00228-009-0748-y","article-title":"The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing","volume":"66","author":"Malhotra","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.euf.2024.02.005_b0165","first-page":"620","article-title":"A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older","volume":"46","author":"Wagg","year":"2017","journal-title":"Age Ageing"},{"key":"10.1016\/j.euf.2024.02.005_b0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2125.2011.03961.x","article-title":"A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder","volume":"72","author":"Callegari","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.euf.2024.02.005_b0175","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/ageing\/afr102","article-title":"The impact of anticholinergic burden in Alzheimer\u2019s dementia-the LASER-AD study","volume":"40","author":"Fox","year":"2011","journal-title":"Age Ageing"},{"key":"10.1016\/j.euf.2024.02.005_b0180","doi-asserted-by":"crossref","first-page":"e12290","DOI":"10.1002\/trc2.12290","article-title":"Association between anticholinergic burden and dementia in UK Biobank","volume":"8","author":"Mur","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.euf.2024.02.005_b0185","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1532-5415.2009.02699.x","article-title":"White matter hyperintensities predict functional decline in voiding, mobility, and cognition in older adults","volume":"58","author":"Wakefield","year":"2010","journal-title":"J Am Geriatr Soc"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T12:01:24Z","timestamp":1744545684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456924000221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405456924000221"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2024.02.005","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder\u2013wet Patients over the Age of 75 Years with Mild Cognitive Impairment","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2024.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}